AU645594B2 - Bioerodible implants - Google Patents

Bioerodible implants Download PDF

Info

Publication number
AU645594B2
AU645594B2 AU82678/91A AU8267891A AU645594B2 AU 645594 B2 AU645594 B2 AU 645594B2 AU 82678/91 A AU82678/91 A AU 82678/91A AU 8267891 A AU8267891 A AU 8267891A AU 645594 B2 AU645594 B2 AU 645594B2
Authority
AU
Australia
Prior art keywords
polymer
dosage form
beneficial agent
bioerodible
poly
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU82678/91A
Other languages
English (en)
Other versions
AU8267891A (en
Inventor
Randolph Lee Seward
Chung Shih
Randall V. Sparer
Gaylen M. Zentner
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck and Co Inc
Original Assignee
Merck and Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck and Co Inc filed Critical Merck and Co Inc
Publication of AU8267891A publication Critical patent/AU8267891A/en
Application granted granted Critical
Publication of AU645594B2 publication Critical patent/AU645594B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/593—Polyesters, e.g. PLGA or polylactide-co-glycolide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A61K9/204—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/10—Anthelmintics

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Materials For Medical Uses (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Biological Depolymerization Polymers (AREA)
AU82678/91A 1990-08-22 1991-08-21 Bioerodible implants Ceased AU645594B2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US57074290A 1990-08-22 1990-08-22
US570742 1990-08-22

Publications (2)

Publication Number Publication Date
AU8267891A AU8267891A (en) 1992-02-27
AU645594B2 true AU645594B2 (en) 1994-01-20

Family

ID=24280874

Family Applications (1)

Application Number Title Priority Date Filing Date
AU82678/91A Ceased AU645594B2 (en) 1990-08-22 1991-08-21 Bioerodible implants

Country Status (13)

Country Link
US (1) US5837228A (ja)
EP (1) EP0473223B1 (ja)
JP (1) JP2588328B2 (ja)
AT (1) ATE122230T1 (ja)
AU (1) AU645594B2 (ja)
CA (1) CA2049668C (ja)
DE (1) DE69109581T2 (ja)
DK (1) DK0473223T3 (ja)
ES (1) ES2072530T3 (ja)
IE (1) IE67141B1 (ja)
IL (1) IL99180A (ja)
NZ (1) NZ239370A (ja)
PT (1) PT98708B (ja)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5211951A (en) * 1991-07-24 1993-05-18 Merck & Co., Inc. Process for the manufacture of bioerodible poly (orthoester)s and polyacetals
KR100374098B1 (ko) * 1994-04-08 2003-06-09 아트릭스 라보라토리스, 인코포레이션 조절된방출이식편형성에적합한액체전달조성물
EP1014970A1 (en) * 1997-09-23 2000-07-05 Pfizer Limited Parasiticidal formulations
US6524602B1 (en) * 1998-10-13 2003-02-25 Craig G. Burkhart Polymer delivery system in treatments for parasitic skin diseases
CZ20013269A3 (cs) * 1999-03-11 2002-04-17 Société des Produits Nestlé S. A. Bakterie mléčného kvaąení
US6613355B2 (en) 2000-05-11 2003-09-02 A.P. Pharma, Inc. Semi-solid delivery vehicle and pharmaceutical compositions
US20050042194A1 (en) 2000-05-11 2005-02-24 A.P. Pharma, Inc. Semi-solid delivery vehicle and pharmaceutical compositions
AU2001288829A1 (en) 2000-09-06 2002-03-22 Ap Pharma, Inc. Degradable polyacetal polymers
CA2429898C (en) * 2000-11-16 2011-02-22 Durect Corporation Devices and methods for cholesterol management
US6590059B2 (en) 2001-05-11 2003-07-08 Ap Pharma, Inc. Bioerodible polyorthoesters from dioxolane-based diketene acetals
AUPR602501A0 (en) * 2001-06-29 2001-07-26 Smart Drug Systems Inc Sustained release pharmaceutical composition
AUPR602401A0 (en) 2001-06-29 2001-07-26 Smart Drug Systems Inc Sustained release delivery system
AUPR610501A0 (en) * 2001-07-04 2001-07-26 Smart Drug Systems Inc Treatment of parasitic disease
US20050009762A1 (en) 2003-06-06 2005-01-13 Strobel Michael Albert Application of water and organic solvent soluble ivermectin for topical and oral use
US6627613B2 (en) 2001-07-23 2003-09-30 Michael A. Strobel Application of water and organic solvent soluble ivermectin for topical and oral use
US20040142902A1 (en) * 2001-11-08 2004-07-22 Struijker- Boudier Harry A.J. Implant dosage form and use thereof for the delivery of a cholosterol lowering agent
US6524606B1 (en) 2001-11-16 2003-02-25 Ap Pharma, Inc. Bioerodible polyorthoesters containing amine groups
US20040001889A1 (en) 2002-06-25 2004-01-01 Guohua Chen Short duration depot formulations
US7288609B1 (en) * 2003-03-04 2007-10-30 Advanced Cardiovascular Systems, Inc. Coatings for drug delivery devices based on poly (orthoesters)
CA2525631C (en) * 2003-05-13 2012-12-18 Medtronic, Inc. Moisture curable materials for delivery of agents, methods, and medical devices
CA2575988C (en) 2004-08-04 2014-02-18 Brookwood Pharmaceuticals, Inc. Methods for manufacturing delivery devices and devices thereof
US20070265329A1 (en) * 2006-05-12 2007-11-15 Devang Shah T Methods for the prevention of acute and delayed chemotherapy-induced nausea and vomiting (CINV)
US20070264338A1 (en) * 2006-05-12 2007-11-15 Shah Devang T Base-stabilized polyorthoester formulations
US20070264339A1 (en) * 2006-05-12 2007-11-15 Ap Pharma, Inc. Base-stabilized polyorthoester formulations
EP2044142A2 (en) 2006-06-29 2009-04-08 Medtronic, Inc. Poly(orthoester) polymers, and methods of making and using same
WO2009085952A1 (en) 2007-12-20 2009-07-09 Brookwood Pharmaceuticals, Inc. Process for preparing microparticles having a low residual solvent volume
US8940315B2 (en) 2008-04-18 2015-01-27 Medtronic, Inc. Benzodiazepine formulation in a polyorthoester carrier
US8956642B2 (en) 2008-04-18 2015-02-17 Medtronic, Inc. Bupivacaine formulation in a polyorthoester carrier
US20100152227A1 (en) * 2008-12-11 2010-06-17 A.P. Pharma, Inc. Methods for Enhancing Stability of Polyorthoesters and Their Formulations
CN103153313A (zh) 2010-07-30 2013-06-12 法国诗华动物保健公司 用于防治恶丝虫侵袭的组合物
EP3682887A1 (en) * 2010-07-30 2020-07-22 Ceva Sante Animale Compositions comprising ivermectin for treating heartworm infestation
CA2857958C (en) 2011-12-02 2020-08-25 Merial Limited Long-acting injectable moxidectin formulations and moxidectin crystal forms
CA3167217A1 (en) 2020-01-13 2021-07-22 Durect Corporation Sustained release drug delivery systems with reduced impurities and related methods

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4639366A (en) * 1984-06-06 1987-01-27 Merck & Co., Inc. Polymers containing pendant acid functionalities and labile backbone bonds
US4764764A (en) * 1984-11-27 1988-08-16 Honeywell Inc. Write-protect apparatus for bit mapped memory
US4765973A (en) * 1984-06-06 1988-08-23 Merck & Co., Inc. Polymers containing pendant acid functionalities and labile backbone bonds

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4093709A (en) 1975-01-28 1978-06-06 Alza Corporation Drug delivery devices manufactured from poly(orthoesters) and poly(orthocarbonates)
US4150108A (en) * 1975-12-29 1979-04-17 Graham Neil B Injectable medicinal compositions
JPS5441319A (en) * 1977-06-28 1979-04-02 Uni Sutorasukuraido Za Pharmaceutical composition for treating tropic desease
US4356166A (en) * 1978-12-08 1982-10-26 University Of Utah Time-release chemical delivery system
US4304767A (en) * 1980-05-15 1981-12-08 Sri International Polymers of di- (and higher functionality) ketene acetals and polyols
US4636387A (en) * 1982-06-21 1987-01-13 Research Corporation Anesthetic polyorganophosphazenes
CS254355B1 (en) * 1985-04-10 1988-01-15 Vladimir Saudek Soluble and biodegradatable copolymeres activated for bond of biologicaly active substances
US4764364A (en) * 1986-02-25 1988-08-16 S R I International Method of preparing bioerodible polymers having pH sensitivity in the acid range and resulting product
AU2902289A (en) * 1987-12-08 1989-07-05 Mark Chasin Method of forming bioerodible implants for improved controlled drug release

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4639366A (en) * 1984-06-06 1987-01-27 Merck & Co., Inc. Polymers containing pendant acid functionalities and labile backbone bonds
US4765973A (en) * 1984-06-06 1988-08-23 Merck & Co., Inc. Polymers containing pendant acid functionalities and labile backbone bonds
US4764764A (en) * 1984-11-27 1988-08-16 Honeywell Inc. Write-protect apparatus for bit mapped memory

Also Published As

Publication number Publication date
CA2049668A1 (en) 1992-02-23
IL99180A (en) 1998-01-04
EP0473223B1 (en) 1995-05-10
PT98708B (pt) 1999-01-29
PT98708A (pt) 1992-08-31
DE69109581D1 (de) 1995-06-14
US5837228A (en) 1998-11-17
JP2588328B2 (ja) 1997-03-05
EP0473223A1 (en) 1992-03-04
JPH04230621A (ja) 1992-08-19
NZ239370A (en) 1994-04-27
DK0473223T3 (da) 1995-07-10
IE67141B1 (en) 1996-03-06
ES2072530T3 (es) 1995-07-16
AU8267891A (en) 1992-02-27
IL99180A0 (en) 1992-07-15
DE69109581T2 (de) 1996-01-18
ATE122230T1 (de) 1995-05-15
CA2049668C (en) 2002-11-12
IE912965A1 (en) 1992-02-26

Similar Documents

Publication Publication Date Title
AU645594B2 (en) Bioerodible implants
US5211951A (en) Process for the manufacture of bioerodible poly (orthoester)s and polyacetals
EP0635272B1 (en) Liquid absorbable copolymers for parenteral applications
US5176907A (en) Biocompatible and biodegradable poly (phosphoester-urethanes)
US4130639A (en) Absorbable pharmaceutical compositions based on isomorphic copolyoxalates
Heller Poly (ortho esters)
US8106146B2 (en) Therapeutic polymers and methods of generation
Heller et al. Use of poly (ortho esters) for the controlled release of 5-fluorouracyl and a LHRH analogue
HU186904B (en) Process for producing retarde pharmaceutical compositions
EP0258780A2 (en) Polyesters containing alkylene oxide blocks as drug delivery systems
AU2014203350B2 (en) Subcutaneous implants containing a degradation-resistant polylactide polymer and a lh-rh analogue
CA2108680A1 (en) Improved retard systems for the sustained release of medicinal and/or biological valuable materials from a depot carrier material
US5254345A (en) Poly(orthocarbonate acetal) bioerodible polymers
JP2704330B2 (ja) 生分解性重合体